Combined consecutive bilateral occlusive vasculitis and CMV retinitis in immunosuppression with JAK Inhibitor Since their introduction in 2012, Janus kinase (JAK) inhibitors have transformed the management of autoimmune diseases in both systemic and ophthalmological conditions. However, their expanding use ha...

This report illustrates a case of combined consecutive bilateral occlusive vasculitis and cytomegalovirus (CMV) retinitis during treatment with upadacitinib, a selective Janus kinase (JAK1) inhibitor. A literature review is included.

bit.ly/cjo_JAK-inhi...

#Ophthalmology #Uveitis #JAKInhibitor

Atopic Dermatitis (AD) is more than just dry skin—it's a complex immune failure.

We reviewed Abrocitinib, the new selective JAK1 inhibitor that is changing the game for moderate-to-severe eczema.

doi.org/10.2174/0115743624291067240307051246

#WeiPublications #Dermatology #Eczema #JAKinhibitor

New article to read! Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis.

➡️ No significant survival benefit but reassuring safety profile.

🔗 doi.org/10.1111/joim.70047

#dermatomyositis #JAKinhibitor @univlille.bsky.social

China NMPA Conditionally Approves Golixitinib Capsules for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs

#Medsky🧪 #oncosky #pharmasky #Immunotherapy in cancer is often limited by adverse autoimmune effects incl T1D A study published in @jci-insight.bsky.social found #JAKinhibitor #ruxolitinib protects against ICI-T1DM in 🐁 & impairs T follicular helper cell differentiation in patients with ICI-T1DM.

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I

Filgotinib offers new promise for managing Crohn’s disease Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving clinical and endoscopic remission in phase 3 trials. The ...

Filgotinib offers new promise for managing Crohn’s disease 🌟💊🌍 www.news-medical.net/news/2024120... #CrohnsDisease #Filgotinib #JAKInhibitor #ClinicalTrials #Gastroenterology #Health #Medical #PatientCare @thelancet.bsky.social

MHRA grants marketing authorisation for LEO Pharma’s eczema cream - Pf Media The MHRA has granted marketing authorisation for LEO Pharma’s cream for the treatment of patients with moderate to severe chronic hand eczema.

#dermatology #skindisease #MHRA #Anzupgo #delgocitinib #eczemacream #handeczema #chronichandeczema #LEOPharma #UKMHRA #topicalJAKinhibitor #JAKinhibitor #phase3clincialtrials #DELTA1clincialtrial #DELTA2clinicaltrial #DELTA3openlabelextensiontrial #NICE #NHS
pf-media.co.uk/news/mhra-gr...